Anthem Biosciences files revised investor presentation for Q2 FY2026 results
The company uploaded an unaudited consolidated financial results presentation for the quarter ended 30 June 2026 on 21 July 2026 under Regulation 30 (LODR).
What Anthem Biosciences announced
On 21 July 2026, Anthem Biosciences Ltd filed a revised investor presentation with the Bombay Stock Exchange (BSE) under Regulation 30 (LODR). The presentation contains the company's unaudited consolidated financial results for the quarter ended 30 June 2026. No additional corporate actions, dividend declarations, or capital changes were disclosed in the filing.
Investor presentation details
The filing, identified by BSE reference number 544449, is titled "Revised Investor Presentation for Unaudited Consolidated Financial Results of the Company for the quarter ended June 30, 2026". The document is made available as a PDF on the BSE website. While the filing notice does not enumerate the financial numbers, it signals that the company has prepared a formal slide‑deck for shareholders and analysts, typically covering revenue, profit before tax, net profit, earnings per share, and segment performance.
Key facts at a glance
| Detail | Value |
|---|---|
| Company | Anthem Biosciences Ltd |
| BSE ticker | 544449 |
| Filing date | 21 July 2026 |
| Regulation | 30 (LODR) |
| Document type | Revised Investor Presentation (PDF) |
| Period covered | Quarter ended 30 June 2026 |
| Financials | Unaudited consolidated results |
| Source | BSE filing (PDF) |
Why this matters for investors
Regulation 30 obliges listed entities to disclose material information promptly. By filing the investor presentation, Anthem Biosciences ensures that market participants have timely access to its latest performance metrics, even though the numbers remain unaudited. Investors can review the slides to gauge short‑term trends, compare against prior quarters, and assess the company's operational health ahead of the audited results, which are typically released later in the fiscal year.
Conclusion
Anthem Biosciences has complied with its disclosure obligations by uploading a revised investor presentation for Q2 FY2026 on 21 July 2026. The filing provides unaudited financial data for the quarter ending 30 June 2026, but no further details such as exact figures, dividend policy, or capital changes are disclosed in the announcement. Stakeholders should review the PDF on the BSE portal for the complete set of results and await the audited statements for final confirmation.
Frequently asked questions
Related stocks
Source filing: view original